Théroux, P.

patient /iiia trial glycoprotein death placebo effect treatment inhibitor event syndrome receptor 30 days reduction infarction platelet benefit age subgroups pursuit ratio group blocker subgroups heparin 1·00 intervention infusion study troponin elevation treatment effect table difference baseline prism-plu lancet publishing group revascularisation investigator heart lancet article prism trial-specific odds ratios interaction efficacy therapy inhibition outcome complication 30- m l simoons march analysis women control heart.bmj.com concentration downloaded result endpoints study drug infusion 5 days non-fatal mi randomized period meta-analysi evidence /control tirofiban randomisation abciximab paragon-b paragon-a treatment benefit r m califf boersma non-fatal gusto-iv lamifiban study-drug infusion